These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28645940)

  • 1. T-cell Receptors for Clinical Therapy:
    Kunert A; Obenaus M; Lamers CHJ; Blankenstein T; Debets R
    Clin Cancer Res; 2017 Oct; 23(20):6012-6020. PubMed ID: 28645940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD; Harris DT; Kranz DM
    Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
    Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput discovery of cancer-targeting TCRs.
    Bunse L; Green EW; Platten M
    Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.
    Hammerl D; Rieder D; Martens JWM; Trajanoski Z; Debets R
    Trends Immunol; 2018 Nov; 39(11):921-936. PubMed ID: 30309702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCR validation toward gene therapy for cancer.
    Green EW; Bunse L; Bozza M; Sanghvi K; Platten M
    Methods Enzymol; 2019; 629():419-441. PubMed ID: 31727252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.
    Spear TT; Wang Y; Smith TW; Simms PE; Garrett-Mayer E; Hellman LM; Baker BM; Nishimura MI
    Mol Ther; 2018 Apr; 26(4):996-1007. PubMed ID: 29503203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
    Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
    Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.
    Kunert A; van Brakel M; van Steenbergen-Langeveld S; da Silva M; Coulie PG; Lamers C; Sleijfer S; Debets R
    J Immunol; 2016 Sep; 197(6):2541-52. PubMed ID: 27489285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
    Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
    Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 19. Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope.
    Gras S; Saulquin X; Reiser JB; Debeaupuis E; Echasserieau K; Kissenpfennig A; Legoux F; Chouquet A; Le Gorrec M; Machillot P; Neveu B; Thielens N; Malissen B; Bonneville M; Housset D
    J Immunol; 2009 Jul; 183(1):430-7. PubMed ID: 19542454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy.
    D'Apice L; Cuccaro F; Varriale S; Cipria D; Sartorius R; Circosta P; Cignetti A; Salerno M; Coscia MR; Oreste U; Marzullo VM; Martini G; Acuto O; De Berardinis P
    J Immunother; 2019 May; 42(4):97-109. PubMed ID: 30865026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.